newsfilter
← Latest News
GlobeNewswire·

Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results

– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – Granted Fast Track Designation for both AXO-AAV